Show simple item record

dc.contributor.authorMcIntosh, Lacey J.
dc.contributor.authorRosen, Max P
dc.contributor.authorMittal, Kriti
dc.contributor.authorWhalen, Giles F.
dc.contributor.authorBathini, Venu G.
dc.contributor.authorAli, Tasneem
dc.contributor.authorEdmiston, Kathryn L.
dc.contributor.authorWalsh, William V.
dc.contributor.authorGerber, Jonathan M
dc.date2022-08-11T08:08:10.000
dc.date.accessioned2022-08-23T15:44:56Z
dc.date.available2022-08-23T15:44:56Z
dc.date.issued2021-05-11
dc.date.submitted2021-05-17
dc.identifier.citation<p>McIntosh LJ, Rosen MP, Mittal K, Whalen GF, Bathini VG, Ali T, Edmiston KL, Walsh WV, Gerber JM. Coordination and optimization of PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination. Cancer Treatment Reviews. 2021 May 11.</p>
dc.identifier.doi10.1016/j.ctrv.2021.102220
dc.identifier.pmid34029956
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27428
dc.description.abstractAs the world embarks on mass vaccination for COVID-19, we are beginning to encounter unintended dilemmas in imaging oncology patients; particularly with regards to FDG PET/CT. In some cases, vaccine-related lymphadenopathy and FDG uptake on PET/CT can mimic cancer and lead to confounding imaging results. These cases with findings overlapping with cancer pose a significant dilemma for diagnostic purposes, follow-up, and management leading to possible treatment delays, unnecessary repeat imaging and sampling, and patient anxiety. These cases can largely be avoided by optimal coordination between vaccination and planned imaging as well as preemptive selection of vaccine administration site. This coordination hinges on patient, oncologist, and radiologists’ awareness of this issue and collaboration. Through close communication and patient education, we believe this will eliminate significant challenges for our oncology patients as we strive to end this pandemic.
dc.language.isoen_US
dc.relation.urlhttps://doi.org/10.1016/j.ctrv.2021.102220
dc.subjectOncologic imaging
dc.subjectCOVID-19 vaccine
dc.subjectvaccination
dc.subjectcancer
dc.subjectFDG PET/CT
dc.subjectDiagnosis
dc.subjectHemic and Lymphatic Diseases
dc.subjectInfectious Disease
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectPublic Health
dc.subjectRadiology
dc.subjectVirus Diseases
dc.titleCoordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination
dc.typeJournal Article
dc.source.journaltitleCancer Treatment Reviews
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/225
dc.identifier.contextkey22964872
html.description.abstract<p><p id="x-x-x-x-sp0010">As the world embarks on mass vaccination for COVID-19, we are beginning to encounter unintended dilemmas in imaging oncology patients; particularly with regards to FDG PET/CT. In some cases, vaccine-related lymphadenopathy and FDG uptake on PET/CT can mimic cancer and lead to confounding imaging results. These cases with findings overlapping with cancer pose a significant dilemma for diagnostic purposes, follow-up, and management leading to possible treatment delays, unnecessary repeat imaging and sampling, and patient anxiety. These cases can largely be avoided by optimal coordination between vaccination and planned imaging as well as preemptive selection of vaccine administration site. This coordination hinges on patient, oncologist, and radiologists’ awareness of this issue and collaboration. Through close communication and patient education, we believe this will eliminate significant challenges for our oncology patients as we strive to end this pandemic.</p>
dc.identifier.submissionpathcovid19/225
dc.contributor.departmentDepartment of Surgery, Division of Surgical Oncology
dc.contributor.departmentDepartment of Medicine, Division of Hematology Oncology
dc.contributor.departmentDepartment of Radiology


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record